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Abstract: Non-steroidal anti-inflammatory drugs (NSAIDs) are the group of drugs most commonly 
used in medicine. They are available over the counter to treat fevers and pains of various origins. 
The clinical and pharmaceutical analysis of these drugs requires effective analytical procedures 
for drug quality control, pharmacodynamic and pharmacokinetic studies. This article presents 
the spectrophotometric method that was used to analyze selected drugs from the NSAID group. 
The conditions for the determination of selected coxibs and oxicams in the UV range with the use of 
microplates have been developed. The presented procedure has been validated in accordance with 
the requirements, guaranteeing reliable results. The obtained results give the basis for the conclusion 
that the method can be successfully used in the quality control of pharmaceutical preparations with a 
small amount of available sample.
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1. Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are a group of drugs most commonly used in 
human and veterinary medicine. M any of them are available over the counter, most often to treat 
fever and moderate pain. NSAIDs include chemical compounds of various structures and therapeutic 
applications. However, they share certain characteristics, i.e., identical basic pharmacological properties, 
similar basic mechanisms of action as well as similar side effects. In addition, all drugs in this group 
are acidic in nature (pK values in the range 3.0-5.0). NSAID molecules can contain both hydrophilic 
(carboxyl or enol groups) and lipophilic (e.g., aromatic ring) groups. Due to their acidic nature, they are 
present in gastric juice in a protonated form. Also in the small intestine, there are favorable conditions 
for the absorption of weak acids due to the environment prevailing there. NSAIDs may exist in an 
ionized form in plasma. They are characterized by a very high level of plasma protein binding (>97%) 
and values of the volume of distribution ranging from 0.1 to 1.0. Most NSAIDs are metabolized in 
the liver through oxidation and conjugation of inactive metabolites which are excreted in the urine or 
bile. The metabolism of NSAIDs may be disturbed in some disease states, then accumulation of the 
drug may occur even at normal doses [1- 3]. Disease entities in which NSAIDs are used include pain 
accompanying infection, metabolic and neoplastic diseases, systemic diseases of connective tissue, 
degenerative joint diseases, neurovascular disorders and other diseases accompanied by inflammatory 
and pain symptoms from the skeletal system [4,5] . The mechanism of action of this group of drugs 
is associated with the inhibition of the transformation of eicosanoids (prostanoids, leukotrienes), 
which are products of transformation of polyunsaturated fatty acids. The substrate for this synthesis is 
arachidonic acid, which is released from cell membranes by phospholipase A2. The activity of this 
enzyme is stimulated by calmodulin, bradykinin, thrombin and calcium, while inhibition is caused 
by glucocorticosteroids.
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The NSAID group also includes oxicams and coxibs (Figure 1), substances whose mechanism of 
action is to fnhibit COX prostaglandin cyclooxygenase. There are; two isoenzymes: COX-1 (a cellular 
enzyme responsible for the synthesis of prootaglandins necessary for physiological prooesses) and 
COX-2 (appears in cells where the inflammotory process takes place and determines the formation oS 










Figure 1. Chemical structures of analyzed compounds.
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Talcing; the chemical structure into accounte oxicams are classified as derivatives of enolic adds. 
Drugs belongeng to this family include piroxicam, tenoxicam and meloxicam— drugs with strong, 
long-lasting anti-inflammatory and an algesic effects that are rel!tively welt tolerated [2,3]. Oxicams are 
quickly absorbed from the gastrointestinal tract and are over 90% bound to plasma proteins. They are 
meSaboИzed mainly to glucuronidos and excreted in feces and urine. "The half-life of oxicamsi ranging 
from 30-40 h, allows for once-a-day dosing of the drug.
Deugs belonging to the coxib group are selective for the COX-2 isoform. The development of 
drugs that selectively inhibit the indudble cyclooxygenase isoUorm ellowed for a significant reduction 
ie side effectf whilc maintaining ou.ll anti-innlmmatory and analgesic activity. It lias been shown than 
these drugs have an anti-inflammaaory effect comparable 1o  non-setective cyclooxygenase inhibitors, 
and at the same time they are almost completely devoid of adverse effects on the gastrointestinal 
tract [4,8]. otudies that assessed the condition erf the gtaetric mucosa by using gastroscopy have shown 
that the use of coxib is associated with a much lower incidence of ulcer complications than other 
NSAIDs. At the same time, selective COX-2 inhibitors are not without side effects. They are known 
to slow ulcer healing and can under certain conditions impair kidney function. Two generations of 
drugs can be distinguished within the group of coxibs: the 1st generation includes rofecoxib, celecoxib 
and valdecoxib, while the 2nd generation includes etoricoxib and lumiracoxib. The 1st generation 




is 106 to 515 times stronger than COX-1. Celecoxib is a drug of the diarylpyrazole group, which is 
used to relieve symptoms of rheumatoid arthritis and osteoporosis as an analgesic. Administration of 
celecoxib has also been shown to inhibit the development of colorectal adenomas. Contraindication to 
use is caused by an allergy to sulfonamides or acetylsalicylic acid, and caution should be exercised 
in patients with asthma, liver and kidney damage and allergy sufferers. Etoricoxib, belonging to the 
NSAIDs from the dipyridine derivative group, is used in the symptomatic treatment of osteoarthritis, 
rheumatoid arthritis, symptoms of joint inflammation, pain treatment and in the acute phase of gout.
The widespread use of NSAIDs causes the creation of new, more effective combinations, and at 
the same time obliges increasing the quality control of these substances and therapeutic preparations 
so that they are as free as possible from contamination that may remain from the production process or 
arise during the decomposition of active substances or auxiliary. Clinical and pharmaceutical drug 
analysis requires effective analytical procedures to evaluate the quality of pharmacodynamic and 
pharmacokinetic studies. A review of relevant publications shows the use of various analytical methods.
The most widely used techniques of instrumental analysis are optical methods. Each molecule has 
the ability to absorb its characteristic portion of energy provided by electromagnetic radiation at a given 
wavelength. This makes it possible to identify functional groups in the molecule. The basis for the use of 
the spectrophotometric method is to determine the wavelength that has been absorbed and to determine 
the degree of intensity of radiation passing through the tested sample [9]. Spectrophotometric methods 
are a commonly used method, among others, in the study of biochemical processes (monitoring 
enzymatic reactions, determination of reaction products, measurement of the reaction rate) [10- 14] or 
for quick monitoring of enzymatic reactions, both for measuring the reaction rate and determining 
reaction products [15]. Direct analyses are possible only when the wavelength characteristic for the 
determined component is not disturbed by other components or by background absorption [16,17].
The available literature includes spectroscopic methods used in the analysis of selected compounds. 
Tenoxicam in various pharmaceutical forms was determined spectrophotometrically with the use of 
organic or inorganic reagents (such as alizarin or potassium iodide) at visible range [18- 20]. Methylene 
blue solution and orthophosphate(V) buffer (pH 8) were used for the determination of meloxicam in 
tablets, capsules and suppositories, and the assays were carried out at the maximum absorption of 
653.5 nm [21]. Another author's developed method involved the use of a 0.1 mol/L NaOH solution 
and the chosen wavelength was 362 nm [22]. Taha et al. carried out the determination of meloxicam 
in pharmaceuticals using a solution of 7-chloro-4-nitrobenz-2-oxy-1,3-diazole (NBD-Cl) and acetone, 
at Л =  535 nm [20]. UV spectrophotometric methods were used to analyze celecoxib and tizanidine 
hydrochloride in a 0.1 mol/L sodium hydroxide solution at an absorption maximum of 251.2 nm [23,24]. 
Two spectrophotometric methods (at 253.2 or 509.2 nm) have also been developed for the quantification 
of celecoxib in capsules [23,25]. Etoricoxib was analyzed using a different solvent system (90% methanol 
and NaOH aqueous solution) [23]. Two methods have been developed: direct for drug analysis in 
tablets and indirect for determining drug concentration in human plasma (extraction to acetonitrile 
and ethyl acetate) [23,26].
Separation methods, i.e., liquid chromatography (HPLC), gas chromatography, thin-layer 
chromatography and electrophoresis occupy a permanent place in this industry. These methods, especially 
HPLC, are widely used, however, they generally require complex and expensive equipment [27- 30].
The aim of the presented study was to determine the conditions of quantitative microanalysis of 
selected drugs from the group of oxicams and coxibs with the use of the spectrophotometric method in 
the UV range. Optimization of the conditions and validation of the developed analytical procedure 
will enable the determination of the content of tenoxicam, meloxicam, celecoxib and etoricoxib in 
pharmaceutical preparations using very small amounts of solutions on OptiPlate plates. The presented 
procedure is a rapid and economical (low0cost and non-polluting conditions) method for quantitative 
determination of selected drugs that can be successfully applied in laboratories.
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2. Materials and Methods
2.1. Reagents and Apparatus
The tests were performed using Spectrophotometer VICTOR™ X4 Multilabel Plate Reader 
(PerkinElmer) with OptiPlate 96 quartz bottom plates. All weights were made using an analytical 
balance with accuracy of 1 pg (Radwag, Poland). Methanol of analytical grade was purchased from 
POCH Gliwice, Poland. Standard substances were purchased from: tenoxicam (T0909, Sigma-Aldrich, 
Poznan, Poland), meloxicam (PHR1799, Supelco, Poland), celecoxib (PHR1683, Sigma-Aldrich, Poznan, 
Poland) and etoricoxib (31097, Supelco, Poland).
2.2. Pharmaceutical Preparations
The analyzed pharmaceutical preparations included: Tilcotil (1), tablets containing 20 mg of 
tenoxicam (No F0140, Roche, France); Tilcotil (2), tablets containing 20 mg of tenoxicam (No F0141, 
Roche, France); Meloxicam, tablets containing 7.5 mg of meloxicam (No 0010605, Grodzkie Zakłady 
Farmaceutyczne “Polfa" Sp z.o.o., Poland); Mobic, tablets containing 7.5 mg of meloxicam (No 902471, 
Boehringer Ingelheim, Germany); Mobic, tablets containing 15 mg of meloxicam (No 103123, Boehringer 
Ingelheim, Germany); Opokan, tablets containing 7.5 mg of meloxicam (No 01AF0918, Aflofarm 
Farmacja Polska Sp. z.o.o., Poland); Celebrex, capsules containing 200 mg of celecoxib (No 93870, 
Pfizer); Celebrex (1), capsules containing 100 mg of celecoxib (No 1507660DH, Pfizer); Celebrex 
(2), capsules containing 100 mg of celecoxib (No CD5629, Pfizer); Acroxia, tablets containing 
120 mg of etoricoxib (No 0283210, Merck Sharp&Dohme); Acroxia, tablets containing 90 mg of 
etoricoxib (No NA43020, Merck Sharp&Dohme); Acroxia, tablets containing 60 mg of etoricoxib 
(No 0282500, Merck Sharp&Dohme); Acroxia MSD, tablets containing 60 mg of etoricoxib, (No NA44450, 
Merck Sharp&Dohme).
2.3. Solutions for Analysis
A series of standard solutions of individual substances (tenoxicam, meloxicam, celecoxib and 
etericoxib) were prepared in methanol by weighing the appropriate amounts of the substance into 
10.0 mL flasks in order to obtain 0.02% (m/v) solutions. The obtained solutions were diluted at a further 
stage of the research, obtaining successively solutions with a concentration of 0.001 and 0.0005 % (m/v).
Preparation solutions: The appropriate masses of tablets or capsules, ground in a mortar, 
were weighed and dissolved in methanol to obtain solutions with the appropriate concentrations. 
The contents were shaken for 15 min and the filtered extracts were analyzed.
2.4. Conditions for the Determination o f Substances
The prepared standard solutions of the analyzed substances and the solutions of preparations 
were subjected to spectrophotometric analysis on OptiPlates with a quartz bottom at a wavelength of 
Л =  260 nm (Figure 2).
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Figure 2. A sample image of spectrophotometric assay obtained by a VICTORTMX4 microplate reader.
2.5. Validation of the Method
A criteria for drug quality must be defined and measurable. The process that enables verification of 
the correctness of the selected method is validation. The validation process allows us to assess whether 
a given measurement method with its analytical parameters can be used in the routine laboratory. 
Thanks to that, the results obtained in specific studies thanks to a specific procedure are appropriate 
in relation to the intended purpose. Parameters taken into account during method validation are: 
specificity and selectivity, precision expressed as direct and indirect precision, accuracy, linearity, limits 
of detection and quantification and the range of the method [31].
2.5.1. Precision
Precision determines the degree of agreement between individual analysis results. A  measure 
of precision is the -value of the standard deviation (SD) or the relative standard deviation (RSD,0%o). 
Precision inc ludes two concepts : repeatab iliiy and reproducibility. Repeatability expresses the precision 
oc determinations made in short time interval, by ihe came analyst and under the same conditions. 
Reproducibility allows us to assess whether the method leads to the same resulis when performed 
by different analysts, using solvents from various manufacturers, while maintaining the parameters 
required in the description of the method.
2.5.2. Accuracy
Accuracy allows us to determine the compatibility between the actual value (content, concentration) 
and the value resulting from ths analysis. The measure о if the accuracy of an analytical method is the; 
value of its systematic erros. Accuracy can also be rxpressed as die percent reuovery of the analyte 
addey to the sample.
2.5.3. Linearity
Linearity defined as the ability to obtain analytical measurement results directly proportional 
to the concentration (content) of the analyte in the; sample is usuatly maintained within a yertain 
concentration range. The linear range ol the meihod is determined by plotting the so-calltd calibration 
curve (graphical represeniation of the relationshi p Y =  f(s) , where Y is the measured value;, and c— the 
concentration value of the determined component) and calculation of the correlation coefficient, r.
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2.5.4. Selectivity and Specificity
The determination of the selectivity of the method consists of establishing the conditions for 
determining one component (or several components) in the presence of others. A perfectly selective 
method for one substance is defined as specific.
The sensitivity of the method is a parameter that defines the change of the measured value due to 
the change of the analyte content in the test sample. It is expressed as the slope of the calibration curve 
and numerically equal to the slope of the straight line. The sensitivity of the analytical method is higher 
the greater the change in the measured value is, leading to a small change in the analyte concentration.
2.5.5. Limit of Detection (LOD) and Limit of Quantification (LOQ)
The limit of detection is the smallest amount of a test substance in a sample that can be detected 
but not necessarily determined with adequate accuracy. This parameter can be determined according 
to the formula:
LOD =  3 ^  
a
where: a is the slope of the stright line, Se is the standard deviation of the estimate. The limit of 
quantification is the smallest amount of test substance in a sample that can be quantified with sufficient 
precision and accuracy. It is determined by the formula:
LOQ =
where: a is the slope of the straight line and Se is the standard deviation of the estimate.
2.5.6. The Range of the Method
The range of the method is the interval between the minimum and maximum content of the 
active substance in the test sample for which the analytical method has a definite linearity, accuracy 
and precision.
2.6. Determination of Active Substances in Selected Pharmaceutical Preparations
In order to determine the content of the analyzed substances in pharmaceutical preparations, 
Optiplte 96 microplates were used. Each well was filled with 100 gL of standard solutions (0.001% (m/v) 
concentration for tenoxicam and etoricoxib and 0.0005% (m/v) for meloxicam and celecoxib) and 100 mL 
of test solutions, and then 200 gL of methanol was added to each solution. After putting the plate in the 
spectrophotometer, the absorbance values of all the solutions were measured at 260 nm. Measurements 
were made in triplicate, using the mean absorbance values for calculations.
3. Results and Discussion
A new procedure for the determination of tenoxicam, meloxicam, etoricoxib and celecoxib 
in pharmaceutical preparations has been developed. The analysis was performed with the 
spectrophotometric method using Optiplate 96 microplates. For quantitative determinations, 
absorbance values obtained for standard and test solutions for individual components were used. In the 
preliminary stage of the work, the developed method was validated by establishing the parameters of 
accuracy, linearity, quantification and detection limits and precision.
In order to determine the precision, solutions of individual standard substances and solvent 
(methanol) were placed on the Optilate 96 plate in the following proportions: 100 gL of the substance 
solution and 200 gL of methanol. Then the absorbance value was measured at Л =  260 nm. The obtained 
results of absorbance were the basis for determining the intra-day precision. One week later, solutions 
of individual substances were prepared in an analogous manner, the absorbance was measured and 
the inter-day precision was determined. The received values are summarized in Table 1.
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Table 1. Results of precision with statistical evaluation.
Substance
Intra-Day Precision Inter-Day Precision
Am SD SDm RSD,% Am SD SDm RSD,%
Tenoxicam 0.4333 0.0029 0.0009 0.67 0.4257 0.0031 0.0010 0.73
Meloxicam 0.4472 0.0036 0.0011 0.80 0.4546 0.0033 0.0011 0.73
Etoricoxib 0.5372 0.0033 0.0010 0.62 0.5532 0.0018 0.0006 0.32
Celecoxib 0.06240 0.0030 0.0009 0.48 0.6451 0.0030 0.0010 0.49
Am—arithmetic mean of absorbance; SD—standard deviation; SDm—standard deviation of the mean; 
RSD,%—relative standard deviation.
The percentage of recoverywas established by adding a known amount of the analyte (80,100 and 
120%) to the test sample and then determining with the developed procedure (Table 2).
Tabls 2. Rerults of tire accuracy of the method with statistical evaluation.
Substance Accuracy
Statistical Data
xm SD Sxm RSD,%
80% 90.05 2.1753 0.8881 2.42
Tenoxicam 100% 100.91 1.9248 0.7858 1.91
120% 98.82 1.8401 0.7512 1.86
80% 100.47 2.8261 1.1537 2.81
Meloxicam 100% 97.70 1.8089 0.7385 1.85
120% 98.37 1.9905 ;120..8.126 2.02
80% 99.99 1.5382 0.(2279 1.54
Etoricoxib 100% 100.51 1.8622 0.7.019 . ;. . 1.85
120% 959.82 2.2460 ;. .0.. 9169 2.25
80% 100.30 2.4674 1.0073 2.46
Celecoxib 100% 959.99 2.0409 0.8332 2.04
120% 99.11 1.5011 0.6128 . ;. . 1.51
xm—arithmetic mean; SD—standard deviation; Sxm—standard deviation of the mean; RSD,%—relative 
standard deviation.
On the basis of the measured absorbance values at the wavelength Л =  260 nm for increasing 
concentrations of tenoxicam, meloxicam, etoricoxib and celecoxib, the dependences of absorbance on 
the concentration of the substance were plotted (Figure 3). They were found to be linear in the tested 
ccncsnteaticn rongs, and the parameters of tine; calibration curve are presented in Table 3.
Baced on the determined linearity parameters, the LOD and LOQ for individual substances were 
crlculated, and the results are presented in Thble 4.
o.o   ------------------------------------------
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Figure 3. An example plot of absorbance (A) versus concentration (c) for meloxicam solutions.
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Table 3. Linear regression parameters.
Substance Calibration Curve EquationA = a c+ b r Sa Sb Se
Tenoxicam A == 0.1725 x c + 0.0804 0.9946 0.0073 0.0206 0.0346
Meloxicam A == 0.1037 x c + 0.0535 0.9994 0.0015 0.0085 0.0143
Etoricoxib A == 0.1489 x c + 0.0550 0.9979 0.0060 0.0168 0.0283
Celecoxib A = 0.2535 x c + 0.1289 0.9983 0.0039 0.0220 0.0369
A—absorbance; c—concentration (%); Sa—standard deviation of the slope; Sb—standard deviation of the intercept; 
Se—standard deviation of the estimate.
Table 4. Limit of Detection (LOD) and Limit of Quantification (LOQ) values.





Based on the obtained results, it was found that the developed method is characterized by a wide 
range of linearity (2.0-5.0 pg/mL for tenoxicam, 1.3-10.0 pg/mL for meloxicam, 1.9-5.0 pg/mL for 
etoricoxib, 1.4-5.0 pg/mL for celecoxib) for all analyzed substances with a correlation coefficient (r) 
ranging from 0.9946 to 0.9994, good precision (RSD ranging from 1.51 to 2.81%) and the appropriate 
accuracy (an average recovery value of 98%). Thus, it meets the requirements for analytical procedures 
and can be used to determine the content of selected substances in pharmaceutical products.
Six pharmaceutical preparations containing tenoxicam and meloxicam, and seven preparations 
containing etoricoxib and celecoxib were tested. Ten measurements were made for each of the 
preparations. The obtained absorbance values were used to determine the content of active substance 
in individual preparations. Statistical evaluation was performed for each series of results and the 
obtained values are summarized in Table 5 .
Table 5. Results of the determination of selected active substances with statistical evaluation.
Preparation Content
Statistical Evaluation
xm SD SDxm RSD,%
Tilcotil (1)
20 mg of tenoxicam
16.61 16.51 16.60 16.37 
16.63 16.49 16.36 16.52 
16.50 16.38
16.50 0.10 0.03 0.61
Tilcotil (2)
20 mg of tenoxicam
17.35 17.49 17.25 17.25
17.06 17.06 17.50 17.50 
17.50 17.35
17.35 0.18 0.06 1.04
Mobic 
7.5 mg of meloxicam
6.88 7.02 7.07 6.94
7.01 6.89 7.09 7.06 
7.08 6.94
7.00 0.08 0.03 1.14
Mobic 
15 mg of meloxicam
9.73 9.78 9.37 9.67
9.55 9.39 9.74 9.49 
9.58 9.66
9.60 0.15 0.05 1.51
Meloksykam 
7.5 mg of meloxicam
6.97 6.99 7.04 7.07
6.97 6.97 7.17 7.18 
7.20 7.12
7.07 0.09 0.03 1.32
Opokan 
7.5 mg of meloxicam
7.48 7.51 7.46 7.51 
7.47 7.52 7.52 7.47 
7.45 7.48
7.49 0.03 0.01 0.35




xm SD SDxm RSD,%
Arcoxia 
120 mg of etoricoxib
89.32 91.58 91.58 89.32
91.58 89.83 88.74 91.57 
91.58 89.32
90.44 1.22 0.39 1.35
Arcoxia 
90 mg of etoricoxib
60.83 61.35 60.83 60.83
62.88 62.37 62.37 62.88 
62.88 62.37
61.96 0.90 0.28 1.45
Arcoxia 
60 mg of etoricoxib
49.04 47.16 49.42 49.04
48.66 48.29 49.42 49.04 
47.16 49.42
48.67 0.87 0.28 1.79
Arcoxia MSD 
60 mg of etoricoxib
50.06 48.96 48.98 50.06 
49.36 48.60 49.74 49.36 
48.60 49.74
49.35 0.55 0.17 1.12
Celebrex 
200 mg of celecoxib
188.22 188.02 187.59 187.67
181.64 181.63 187.69 87.62 
187.71 187.60
186.54 2.59 0.82 1.39
Celebrex (1)
100 mg of celecoxib
91.61 91.11 89.10 91.62 
93.95 90.61 90.61 92.95 
90.10 90.10
91.18 1.43 0.45 1.57
Celebrex (2)
100 mg of celecoxib
98.32 101.58 99.36 98.32 
102.28 98.83 99.58 101.07 
99.58 101.74
100.07 1.48 0.47 1.47
xm—arithmetic mean; SD—standard deviation; SDxm—standard deviation of the mean; RSD—relative standard 
deviation (%).
In the case of the analysis of selected pharmaceutical preparations, the content of the active 
ingredient ranges from 64% to 100.07% in relation to the value declared by the manufacturers. The lower 
content of active ingredients in relation to the declared values is probably related to the fact that these 
drugs were expired. In these preparations, the active substance could be partially degraded, and 
thus its content in the tablet/capsule was reduced. Comparing the expiry dates of the pharmaceutical 
preparations used in the analysis with the content in the tablet/capsule obtained in the tests, it can be 
noticed that preparations with a shorter expiry date contained a smaller amount of the active substance 
compared to drugs with a longer expiry date. The preparations analyzed within the expiry date 
contained an amount of the active substance in accordance with the declaration on the packaging.
The obtained results allowed us to conclude that the developed method is simple and accurate, 
and the small volumes of the solutions used (a maximum of 300 gL) and the quick analysis time 
(a measurement time of approximately 0.1 s/well) allow them to be used in laboratories for routine 
analyses of chosen NSAIDs.
4. Conclusions
The developed new procedure for the quantification of tenoxicam, meloxicam, etoricoxib and 
celecoxib in pharmaceutical preparations with the UV spectrophotometric method using microplates 
meets the requirements for validation of analytical methods. Due to the simplicity of determination and 
speed of analysis, it can be helpful in routine analyses and quality control of pharmaceutical preparations. 
Spectrophotometric and chromatographic methods with UV detection are analytical techniques widely 
used in analytical laboratories. The HPLC methods described in the literature always involve sample 
pretreatment and large amounts of various components in the mobile phase. HPLC with MS detection 
makes procedures more complicated and accessible to few parties. The described spectrophotometric 
methods also often include sample pretreatment (derivatizaton). The aim of this work was to develop 
a fast and economical method to be used among others in quality control laboratories. Even if the
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results obtained with different techniques are equally accurate, the significant advantages of our 
methodology, compared to other existing methods, are its low cost, non-polluting conditions, simplicity 
of implementation and small sample volume needed for analysis. Therefore, the method can be used 
for routine quality control of selected drugs in pure substance or commercial samples.
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